- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07700056
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
A 52-week Multi-center, Randomized, Double-blind, Placebo Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a global, phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of remibrutinib in adult participants with severe CPUO.
The design includes 4 periods, for a total duration of up to 60 weeks:
- Screening period: up to 4 weeks.
- Double-blind treatment period (treatment period 1, TP1): 24 weeks of double-blind treatment with remibrutinib or matching placebo
- Open-label treatment period (treatment period 2, TP2): 28 weeks of open-label treatment with remibrutinib. The participants randomized to the placebo arm will be switched to remibrutinib at Week 24.
- Safety follow-up period: 4 weeks of treatment-free safety follow-up.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Novartis Pharmaceuticals
- Número de teléfono: 1-888-669-6682
- Correo electrónico: novartis.email@novartis.com
Copia de seguridad de contactos de estudio
- Nombre: Novartis Pharmaceuticals
- Número de teléfono: +41613241111
Ubicaciones de estudio
-
-
-
CABA, Argentina, C1181ACH
- Reclutamiento
- Novartis Investigative Site
-
-
Buenos Aires
-
Caba, Buenos Aires, Argentina, C1119ACN
- Reclutamiento
- Novartis Investigative Site
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000DBS
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8L 3C3
- Reclutamiento
- Novartis Investigative Site
-
-
Quebec
-
Québec, Quebec, Canadá, G1W 4R4
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
-
Seoul, Corea del Sur, 03722
- Reclutamiento
- Novartis Investigative Site
-
Seoul, Corea del Sur, 07804
- Reclutamiento
- Novartis Investigative Site
-
-
Gyeonggi-do
-
Ansan, Gyeonggi-do, Corea del Sur, 15355
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
Alabama
-
Cullman, Alabama, Estados Unidos, 35058
- Reclutamiento
- Aller Vie Health-Cullman
-
Investigador principal:
- John Anderson
-
Contacto:
- Katelyn Craft
- Correo electrónico: kcraft@allervie.com
-
-
Florida
-
Miami, Florida, Estados Unidos, 33126
- Reclutamiento
- Driven Research
-
Investigador principal:
- Javier Alonso Llamazares
-
Contacto:
- Haymara Gonzalez
- Correo electrónico: hgonzalez@drivenclinicalresearch.com
-
-
Georgia
-
Savannah, Georgia, Estados Unidos, 31406
- Reclutamiento
- Aeroallergy Research Laboratories
-
Investigador principal:
- Brad Goodman
-
Contacto:
- Susie Gault
- Número de teléfono: +1 912 356 3619
- Correo electrónico: sgault@coastalallergy.net
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46256
- Reclutamiento
- Dawes Fretzin Clinical Rea Group
-
Investigador principal:
- Kenneth Dawes
-
Contacto:
- Joan Prusa
- Número de teléfono: +1 317 516 5030#102
- Correo electrónico: jprusa@ecommunity.com
-
New Albany, Indiana, Estados Unidos, 47150
- Reclutamiento
- Southern IN Clinical Trials
-
Contacto:
- Misty Humphress
- Correo electrónico: mhumphress@soinct.com
-
Investigador principal:
- Megan Landis
-
-
New York
-
The Bronx, New York, Estados Unidos, 10455
- Reclutamiento
- Equity Medical
-
Investigador principal:
- Michael Cameron
-
Contacto:
- Rocio Vaquero
- Correo electrónico: rvaquero@equity-med.com
-
-
Ohio
-
Boardman, Ohio, Estados Unidos, 44512
- Reclutamiento
- Optima Research-Boardman
-
Investigador principal:
- Patrick Shannon
-
Contacto:
- Sarah Merlo
- Correo electrónico: smerlo@optimatrials.com
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15241
- Reclutamiento
- Allergy and Clinical Immunology Associates
-
Investigador principal:
- Michael Palumbo
-
Contacto:
- Susan Shidel
- Número de teléfono: +1 412 833 4051
- Correo electrónico: Shidel.sue@gmail.com
-
-
South Carolina
-
North Charleston, South Carolina, Estados Unidos, 29420
- Reclutamiento
- National Allergy and Asthma Research LLS
-
Investigador principal:
- John T Ramey
-
Contacto:
- Donnis June Warren
- Número de teléfono: +1 843 820 1036
- Correo electrónico: JWarren@nationalallergyandent.com
-
-
Texas
-
Pflugerville, Texas, Estados Unidos, 78660
- Reclutamiento
- Austin Inst for Clinical Research
-
Investigador principal:
- Edward Lain
-
Contacto:
- Alivia Hernandez
- Número de teléfono: +1 512 279 2545
- Correo electrónico: ahernandez@atxresearch.com
-
-
-
-
Fukuoka
-
Kitakyushu, Fukuoka, Japón, 8078556
- Reclutamiento
- Novartis Investigative Site
-
-
Kanagawa
-
Yokohama, Kanagawa, Japón, 2400013
- Reclutamiento
- Novartis Investigative Site
-
-
Kumamoto
-
Kumamoto, Kumamoto, Japón, 8620950
- Reclutamiento
- Novartis Investigative Site
-
-
Osaka
-
Habikino, Osaka, Japón, 5838588
- Reclutamiento
- Novartis Investigative Site
-
Sakai, Osaka, Japón, 5938324
- Reclutamiento
- Novartis Investigative Site
-
-
Tokyo
-
Tachikawa, Tokyo, Japón, 1900023
- Reclutamiento
- Novartis Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key Inclusion Criteria:
- Participant must be ≥ 18 years of age, at the time of signing the informed consent.
- Participants with chronic pruritus for at least 4 months prior to screening.
- Chronic pruritus considered of unknown origin as assessed by the investigator at baseline (e.g., excluding chronic pruritus related to primary dermatological or systemic conditions, neuropathic or psychogenic origin or secondary to drugs or other allergen exposures).
- Chronic pruritus must affect at least 2 of the following body areas: trunk, arms, or legs (cannot be unilateral and/or dermatomal in distribution).
- Participants with ongoing, severe chronic pruritus despite the use of emollients and who are candidates for systemic therapy.
- Participants must have severe itch defined by a WI-NRS ≥7 at screening; score scale ranges from 0 to 10; higher score indicates worse itch.
- Participants must have an average WI-NRS ≥7 over the 7 days prior to randomization/baseline visit.
- The average WI-NRS score over the preceding 7 days prior to the randomization/baseline visit will be calculated based on the daily WI-NRS scores (0-10).
- Participants must have PGIS of pruritus scored as 3 "severe" at screening and baseline visits.
Key Exclusion Criteria:
- Any active skin conditions (e.g., atopic dermatitis, psoriasis, etc.) that may interfere with the assessment of CPUO.
- Known systemic condition(s) or medication(s) that are considered by the investigator to be the primary cause of current pruritus.
- Known or suspected infectious disease that is active, chronic or recurrent which precludes the participant from participating in the clinical trial as per Investigator´s assessment. These infectious diseases include but are not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis) and/or known or suspected HIV infection.
- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- Significant bleeding risk or coagulation disorders. History of gastrointestinal bleeding, e.g., in association with use of nonsteroidal anti-inflammatory drugs (NSAIDs), that was clinically relevant (e.g., where intervention was indicated or requiring hospitalization or blood transfusion). Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited.
- History or current hepatic disease, including but not limited to, acute or chronic hepatitis, cirrhosis or hepatic failure or aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) levels of more than 1.5 x upper limit of normal (ULN) or International Normalized Ratio (INR) of more than 1.5 at screening.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Remibrutinib
Remibrutinib film coated tablets |
Oral administration of remibrutinib
Otros nombres:
|
|
Experimental: Placebo followed by remibrutinib
Matching placebo. At the Week 24 visit, all participants will receive active treatment (remibrutinib). |
Oral administration of remibrutinib
Otros nombres:
Oral administration of matching placebo. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of participants achieving ≥4 point reduction from baseline in Worst itch Numerical Rating Scale (WI NRS)
Periodo de tiempo: Baseline, Week 12
|
The WI-NRS is a patient-reported outcome (PRO) instrument consisting of a single question that asks participants to rate the severity of their worst itch over a defined period. The score range is from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicate worse itch severity. |
Baseline, Week 12
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of participants achieving ≥4 point reduction from baseline in WI NRS
Periodo de tiempo: Baseline, Week 4
|
The WI-NRS is a PRO instrument consisting of a single question that asks participants to rate the severity of their worst itch over a defined period. The score range is from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicate worse itch severity. |
Baseline, Week 4
|
|
Proportion of participants achieving Patient Global Impression of Severity (PGIS) score of 0 (none) or 1 (mild)
Periodo de tiempo: Week 12
|
The PGIS of pruritus is a PRO measure consisting of a single item that captures the participant's overall self-assessment of the severity of their pruritus (itch) over a defined recall period. The score range is from 0 (none) to 3 (severe). Lower scores indicate better outcome. |
Week 12
|
|
Proportion of participants achieving Patient Global Impression of Severity (PGIS) score of 0 (none) or 1 (mild)
Periodo de tiempo: Week 24
|
The PGIS of pruritus is a PRO measure consisting of a single item that captures the participant's overall self-assessment of the severity of their pruritus (itch) over a defined recall period. The score range is from 0 (none) to 3 (severe). Lower scores indicate better outcome. |
Week 24
|
|
Change from baseline in Pruritus-related Sleep Disturbance Numerical Rating Scale (SD-NRS)
Periodo de tiempo: Week 12
|
The SD-NRS is a PRO instrument used to assess the degree of sleep disturbance caused by pruritus (itch). The score range is from 0 (No sleep disturbance) to 10 (Worst possible sleep disturbance). Higher scores indicate greater sleep disturbance due to pruritus. |
Week 12
|
|
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: Up to Week 52
|
Number of participants with AEs and SAEs. |
Up to Week 52
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CLOU064R12301
- 2025-524497-41 (Otro identificador: EU CTIS number)
- 2025 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .